Inovio Pharmaceuticals, Inc. (INO)
1.25
-0.03
(-2.34%)
USD |
NASDAQ |
Sep 11, 16:00
1.23
-0.02
(-1.60%)
After-Hours: 07:12
Inovio Pharmaceuticals Enterprise Value : 74.26M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 74.26M |
| September 10, 2026 | 76.73M |
| September 09, 2026 | 80.02M |
| September 08, 2026 | 88.25M |
| September 04, 2026 | 89.08M |
| September 03, 2026 | 83.31M |
| September 02, 2026 | 83.31M |
| September 01, 2026 | 80.84M |
| August 31, 2026 | 75.90M |
| August 28, 2026 | 77.55M |
| August 27, 2026 | 75.08M |
| August 26, 2026 | 78.37M |
| August 25, 2026 | 77.55M |
| August 24, 2026 | 74.26M |
| August 21, 2026 | 68.49M |
| August 20, 2026 | 70.96M |
| August 19, 2026 | 78.37M |
| August 18, 2026 | 70.14M |
| August 17, 2026 | 66.02M |
| August 14, 2026 | 61.08M |
| August 13, 2026 | 45.44M |
| August 12, 2026 | 34.73M |
| August 11, 2026 | 34.39M |
| August 10, 2026 | 31.96M |
| August 07, 2026 | 26.33M |
| Date | Value |
|---|---|
| August 06, 2026 | 26.81M |
| August 05, 2026 | 27.07M |
| August 04, 2026 | 25.93M |
| August 03, 2026 | 28.70M |
| July 31, 2026 | 27.07M |
| July 30, 2026 | 25.34M |
| July 29, 2026 | 56.96M |
| July 28, 2026 | 56.14M |
| July 27, 2026 | 50.80M |
| July 24, 2026 | 51.21M |
| July 23, 2026 | 55.32M |
| July 22, 2026 | 58.61M |
| July 21, 2026 | 61.90M |
| July 20, 2026 | 61.08M |
| July 17, 2026 | 63.55M |
| July 16, 2026 | 63.55M |
| July 15, 2026 | 67.67M |
| July 14, 2026 | 66.84M |
| July 13, 2026 | 66.84M |
| July 10, 2026 | 68.49M |
| July 09, 2026 | 69.31M |
| July 08, 2026 | 70.96M |
| July 07, 2026 | 70.96M |
| July 06, 2026 | 66.84M |
| July 02, 2026 | 71.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Fortress Biotech, Inc. | -17.37M |
| Tonix Pharmaceuticals Holding Corp. | 24.36M |
| Kura Oncology, Inc. | 518.62M |
| Spero Therapeutics, Inc. | 16.98M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.012M |
| Total Expenses (Quarterly) | 6.012M |
| EPS Diluted (Quarterly) | -0.0737 |
| Earnings Yield | -94.08% |
| Normalized Earnings Yield | -100.33 |